Seven 6-alkoxypurine arabinosides were synthesized and evaluated for in vitro activity against variceliazoster virus (VZV). The simplest of the series, 6-methoxypurine arabinoside (ara-M), was the most potent, with 50% inhibitory concentrations ranging from 0.5 to 3 ,M against eight strains of VZV. This activity was selective. The ability of ara-M to inhibit the growth of a variety of human cell lines was at least 30-fold less (50% effective concentration, >100 ,uM) than its ability to inhibit the virus. Enzyme studies suggested the molecular basis for these results. Of the seven 6-alkoxypurine arabinosides, ara-M was the most efficient substrate for VZV-encoded thymidine kinase as well as the most potent antiviral agent. In contrast, it was not detectably phosphorylated by any of the three major mammalian nucleoside kinases. Upon direct comparison, ara-M was appreciably more potent against VZV than either acyclovir or adenine arabinoside (ara-A). However, in the presence of an adenosine deaminase inhibitor, the arabinosides of adenine and 6-methoxypurine were equipotent but not equally selective, the adenine congener had a much less favorable in vitro chemotherapeutic index. Again, this result correlated with data from enzyme studies in that ara-A, unlike ara-M, was a substrate for two mammalian nucleoside kinases. Unlike acyclovir and ara-A, ara-M had no appreciable activity against other viruses of the herpes group. The potency and selectivity of ara-M as an anti-VZV agent in vitro justify its further study.
Varicella-zoster virus (VZV) is a DNA virus of the herpesvirus group. It is the causative agent of varicella (chickenpox), a mild but highly infectious childhood disease, and herpes zoster (shingles), the recurrent form of the disease, normally occurring in adults. Significant morbidity often occurs in association with shingles as a consequence of debilitating pain. The antiherpes agent 9-[(2-hydroxyethoxy)methyl]guanine (Zovirax; acyclovir) is currently the most commonly used drug for the treatment of shingles. However, this agent is less potent against VZV than against herpes simplex virus (4), as is reflected in the relatively high doses of acyclovir required to achieve clinical efficacy against VZV (15) . Adenine arabinoside (ara-A) has also been evaluated clinically against VZV but is not generally used because of adverse side effects (15) . In this report we describe the synthesis and in vitro evaluation of a series of 6-alkoxypurine arabinosides as anti-VZV agents with special emphasis on the most potent member of the series, 6-methoxypurine arabinoside [9-(,-D-arabinosyl)-6-methoxy-9H-purine] (ara-M). A direct in vitro comparison of this agent with acyclovir and ara-A is presented.
MATERIALS AND METHODS
Chemistry. The 6-alkoxypurine arabinosides described in this report were synthesized by an enzymatic method (20) . The enzyme catalysts uridine phosphorylase (EC 2.4.2.3) and purine nucleoside phosphorylase (EC 2.4.2.1) were purified as previously described (19) described conditions (19) . In some cases, the enzyme catalysts were immobilized on diethylaminoethyl cellulose (DE-52; Whatman, Kent, United Kingdom). This immobilization was accomplished by mixing solutions of purified purine nucleoside phosphorylase and uridine phosphorylase in a ratio of 10:1. This mixture contained 10 mM potassium phosphate buffer (pH 7.0). DEAE-cellulose was incrementally added to the enzyme solution (50 mg of protein per ml) with gentle mixing at room temperature. When the protein concentration in a filtered sample fell below 0.05 mg/ml, the addition of cellulose was stopped. The protein concentration was determined by the Coomassie blue method (31) with bovine gamma globulin from Bio-Rad (Richmond, Calif.) as the standard. The resulting slurry of itnmobilized enzymes was added directly to the reaction mixtures.
Uracil arabinoside (ara-U) was prepared from 2',2'-anhydro-(l-,-D-arabinofuranosyl)cytosine hydrochloride (U.S. Biochemical Corp, Cleveland, Ohio) (20) . [2-'4C]ara-U was synthesized by incubating [2-'4C]cytosine arabinoside (56 ci/mol; Moravek Biochemicals Inc., Brea, Calif.) with cytidine deaminase (EC 3.5.4.5) from E. coli (20) . Protein was removed from the reaction mixture by ultrafiltration (10,000-molecular-weight cutoff, Centricon; Amicon Corp., Danvers, Mass.), and the product was purified (>99.8%) by reversed-phase chromatography (C2/C18 PepRPC; Pharmacia, Upsala, Sweden) with 2 mM Tris-HCl (pH 7.5) as the eluant. 6-Methoxypurine, 6-ethoxypurine, ara-A, and hypoxanthine arabinoside (ara-H) were purchased from Sigma Chemical Co., St. Louis, Mo. Guanine arabinoside (ara-G) was prepared by adenosine deaminase (EC 3.5.4.4; from calf intestine; Sigma)-catalyzed deamination of 2,6-diaminopurine arabinoside (20) . Acyclovir (29) and the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) (28) were obtained from the Chemical Development Laboratories of this institution. Dowex-l-formate (X8), Dowex-1-hydroxide (X8), and polyacrylamide gel (P-2) were purchased from Bio-Rad.
Solvents were removed from mixtures by rotary evaporation in vacuo at temperatures below 50°C. When a purified product was present in a mixture of water and alcohol, the product was obtained by initial, partial rotary evaporation to remove the alcohol and then by lyophilization. All solvent mixtures are with water as the second component (vol/vol) unless otherwise specified. Elemental analyses were performed by Atlantic Microlabs, Atlanta, Ga., and gave results for C, H, and N within + 0.4% of calculated values. Melting points were obtained on a Thomas Hoover Unimelt apparatus and are uncorrected. UV spectra were obtained with a Gilford recording spectrometer. Mass spectra were obtained from Oneida Research Service, Whitesboro, N.Y., with a Finnegan 45 TFQ mass spectrometer. Optical rotations were determined with a Perkin-Elmer model 241 polarimeter.
ara-M (compound 1). 6-Methoxypurine (26) (241 mmol, 36.2 g) and ara-U (287 mmol, 70 g) were suspended in 1.1 liters of 10 mM potassium phosphate (pH 7.4). Uridine phosphorylase (180,000 IU) and purine nucleoside phosphorylase (1,800,000 IU) absorbed onto 1.72 liters of DEAEcellulose (see above) were added, and the suspension was stirred at 50°C. Four days later, the reaction was filtered, and the filter cake was washed with 10 mM potassium phosphate buffer (pH 7.4) until no UV absorbance was detected. These washes were combined with the filtrate, diluted to 12 liters with water, and, after the pH was adjusted to 10.5, applied to a column (4.8 by 30 cm) containing 1 liter of Dowex-1-formate. The ion exchanger was washed with methanol. Fractions containing the product were combined, and the solvent was removed. The residue was recrystallized from hot water, yielding 50.9 g of compound 1 (ara-M).
9-,-D-Arabinofuranosyl-6-ethoxy-9H-purine (compound 2). 6-Ethoxypurine (3.05 mmol, 0.5 g) and ara-U (6.09 mmol, 1.48 g) were suspended in 100 ml of 10 mM potassium phosphate-0.04% potassium azide (pH 7.4). Uridine phosphorylase (6,000 IU) and purine nucleoside phosphorylase (8,400 IU) were added, and the suspension was stirred at 35°C. After 168 h, an additional 18,000 IU of uridine phosphorylase and 75,600 IU of purine nucleoside phosphorylase were added. Seven days later, the reaction was filtered, and the filtrate was applied to a column of Dowex-1-hydroxide (2.5 by 8 cm). The product was eluted with 90% methanol. Fractions containing the product were combined, and the solvent was removed. The residue was chromatographed in 30% n-propanol on a column (5 by 90 cm) containing P-2 gel. Fractions containing the product were combined, and the solvent was removed, yielding 0.363 g of compound 2, which was analyzed as a 0.3 hydrate.
9 -0 -D -Arabinofuranosyl -6 -n -propoxy -9H -purine (compound 3). 6-n-Propoxypurine (16) (5.6 mmol, 1 g) was combined with 545 ml of an ara-U solution (10.1 mmol, 2.46 g) in 10 mM potassium phosphate and 7% n-propanol. The pH of the reaction mixture was 7.3. Uridine phosphorylase (680 IU) and purine nucleoside phosphorylase (12,000 IU) were added, and the contents were stirred at 35°C. The reaction mixture was filtered after 58 days, and the filtrate was stored at 3°C for 20 h. The resulting precipitate was collected, dissolved in 30% n-propanol, adjusted to pH 10.5, and applied to a column of Dowex-1-formate (2.5 by 5 cm).
The column was washed with 30% n-propanol. Fractions containing the product were combined, and the solvent was removed. The residue was chromatographed on a column (5 by 90 cm) containing P-2 as described for compound 2. The product was further chromatographed in water on a column of P-2 (5 by 90 cm). Fractions containing product were combined; after lyophilization, 0.758 g of compound 3 was recovered and analyzed as a monohydrate.
9 -D -Arabinofuranosyl -6 -isopropoxy -9H-purine (compound 4). 6-Isopropoxypurine (16) (4.9 mmol, 0.96 g) and ara-U (9.04 mmol, 2.2 g) were suspended in a 325-ml solution containing 5 mM potassium phosphate (pH 7.8), 12% n-propanol, uridine phosphorylase (1,300 IU), and purine nucleoside phosphorylase (10,400 IU). This reaction mixture was incubated at 37°C for 148 days and then filtered. The filtrate was concentrated to one-half the volume, and n-propanol was added to a concentration of 30%. This solution was applied to a column of P-2 (5 by 90 cm) and eluted with 30% n-propanol. Fractions containing the product were combined, and the propanol was removed. This concentrate was chromatographed in water three times on columns of P-2 (5 by 90 cm). The yield was 0.277 g of compound 4, which was analyzed as a hemihydrate.
2-Amino-9-i -D-arabinofuranosyl-6-methoxy-9H-purine (compound 5). 2-Amino-6-methoxypurine (2) (18 mmol, 3.02 g) and ara-U (36 mmol, 8.88 g) were suspended in 600 ml of 10 mM potassium phosphate buffer (pH 7.4). Uridine phosphorylase (68,000 IU) and purine nucleoside phosphorylase (680,000 IU) absorbed onto DEAE-cellulose (see above) were added, and the reaction mixture was stirred at 60°C for 18 h. The filtrate from this reaction was adjusted to pH 10.4 and chromatographed on a column of Dowex-1-formate (5 by 15 cm). The eluant was 90% methanol. Further chromatography was performed on silica gel after the product in methanol was loaded onto 100 ml of dry silica. The mobile phase was 95% acetonitrile. Fractions containing the product were combined, dried, dissolved in 95% ethanol, and filtered through a 0.22-jim-pore-size filter. Solvent removal yielded 2.9 g of compound 5, which was analyzed as a hemihydrate.
9-D -D-Arabinofuranosyl -2 -chloro -6 -methoxy -9H -purine (compound 6). 2-Chloro-6-methoxypurine (9) was prepared by refluxing 2,6-dichloropurine in sodium methoxide. The aglycon was purified by silica flash chromatography with chloroform-methanol (9:1) as the mobile phase. Combustion analysis and the proton nuclear magnetic resonance spectra were in agreement with the proposed structure.
2-Chloro-6-methoxypurine (2 mmol, 0.4 g) and 20 ml of methylethylether were warmed in a steam bath to facilitate dissolution. The solution was cooled to 37°C, and ara-U (4 mmol, 1.06 g), 80 ml of 10 mM potassium phosphate (pH 7.4), uridine phosphorylase (6,000 IU), and purine nucleoside phosphorylase (8,400 IU) were added. The enzyme additions were repeated after 4 days at 37°C. Five days later the reaction was filtered. The filtrate was adjusted to pH 10.6 and applied to a column of Dowex-1-formate (2.5 by 8 cm). The eluant was 90% methanol. Further chromatography was performed on silica gel after the product in methanol was loaded onto 50 ml of dry silica gel. The mobile phase was chloroform-methanol (8:2, vol/vol). Fractions containing the product were combined, dried under vacuum, dissolved in 95% ethanol, and filtered through a 0.22-jim-pore-size filter. The solvent was removed, yielding 0.24 g of compound 6.
2-Amino-9-,-D-arabinofuranosyl-6-ethoxy-9H-purine (compound 7). 2-Amino-6-ethoxypurine (2) (2.79 mmol, 0.5 g), ara-U (5.58 mmol, 1.36 g), 100 ml of 10 mM potassium phosphate (pH 7.4), uridine phosphorylase (6,000 IU), and purine nucleoside phosphorylase (8,400 IU) were combined. The mixture was incubated at 37°C for 34 days and then stored at -20°C. After thawing, the precipitate was extracted three times with 100 ml of hot methanol. All filtrates were combined, adjusted to pH 10.6, and chromatographed on a Dowex-l-formate column (2.5 by 8 cm (25) were purified and assayed by using chromatography on polyethyleneimine-cellulose thin layers (thymidine and adenosine kinases) or a spectrophotometric assay (deoxycytidine kinase) as previously described.
Cytotoxicity. The ability of compounds to inhibit the growth of human diploid fibroblast (MRC-5; ATCC CCL 171) cells (35) was assessed in a microwell format. Compounds were prepared in media to appropriate concentrations and serially diluted at twofold intervals. All compounds were assayed in triplicate. Rapidly growing cells (passages 20 through 25) were then harvested by trypsinization, diluted in medium, and added to give 7,500 cells per well in a final volume of 250 RI per well. The cell cultures were incubated in a humidified atmosphere containing 5% CO2 for 96 h. At the end of the incubation period, the cells were stained for DNA (23) . In additional studies, human epithelioid (D98) cells (27) were used in a similar procedure, except that the incubation time was 72 h rather than 96 h. The procedures for evaluating the growth of the human T-cell lines and MT-4 were as previously described (1) .
Virology. Procedures for assigning the activity of compounds against viruses were as previously described: VZV (35) ; human cytomegalovirus (6) RESULTS AND DISCUSSION Chemistry. The 6-alkoxypurine arabinosides (compounds 1 through 7) were synthesized by using enzyme catalysts isolated from E. ccli (20) . Briefly, the synthesis involved the phosphorolysis of ara-U catalyzed by uridine phosphorylase to uracil and a-D-arabinose-1-phosphate. The reaction of the latter intermediate with the appropriate 6-alkoxypurine to form the desired product was catalyzed by purine nucleoside phosphorylase. The net reaction was arabinosyl transfer from ara-U to a purine. Yields, melting points, UV spectra, and optical rotations of the 6-alkoxypurine arabinosides synthesized are presented in Table 1 . The nuclear magnetic resonance spectra are presented in Table 2 .
Cytotoxicity. The most detailed studies were performed with human diploid fibroblasts (MRC-5 cells), since they were the host cells for most of the tests for the sensitivity of VZV to nucleoside analogs. The effects of the 6-alkoxypurine arabinosides (compounds 1 through 7) and relevant reference nucleoside analogs on the growth of these cells are presented in Table 3 . With one exception, none of the 6-alkoxypurine arabinosides was a potent inhibitor of cell growth. In the absence of EHNA, compound 5 was as inhibitory as ara-G. In the presence of EHNA, however, compound 5 was much less toxic than was ara-G, suggesting that compound 5 was converted to ara-G by the action of adenosine deaminase. In the absence of EHNA, ara-H and ara-A were equally inhibitory. In the presence of EHNA, ara-A was the most cytotoxic nucleoside analog studied.
Because it had the most potent anti-VZV activity, ara-M was further evaluated for the inhibition of the growth of other human cells in vitro. It had a 50% effective concentration (EC50) above 100 ,uM for two human T-cell lines (MOLT-4 and MT-4) and an EC50 of 100 ,uM for the human epitheliod cell line D98. Thus, the degree of growth inhibition observed for MRC-5 cells was paralleled by similar levels of growth inhibition in other cell types.
Activity against the Oka strain of VZV. The antiviral activity of the straight-chain 6-alkoxypurine arabinosides (compounds 1 through 3) in Table 3 decreased with increasing chain length. The ethoxy congener (compound 2) and the n-propoxy congener (compound 3) had 50% inhibitory concentrations (IC50s) that were 6-and 18-fold higher than that of the methoxy congener (compound 1). The isopropoxy congener (compound 4) was not significantly active at 100 p,M, whereas the n-propoxy congener had an IC50 of 18 ,uM.
Similarly, the potency of the 2-amino-6-alkoxy congeners decreased with chain length; the methoxy congener (compound 5) was more potent than the ethoxy congener (compound 6). However, the 2-amino-substituted derivatives of both the methoxy and ethoxy congeners were markedly less potent than their 2-unsubstituted counterparts (compound 1 versus compound 5; compound 2 versus compound 1). Substitution in the 2 position with a chlorine atom rather than an amino group (compound 5 versus compound 6) decreased potency even more.
Direct comparisons of the anti-VZV activity of 6-alkoxypurine arabinosides versus those of hypoxanthine, guanine, and adenine are provided in Table 3 . ara-H and ara-G were equipotent but were 30 times less active than ara-M (compound 1). ara-A was also considerably less potent than ara-M. However, when the rapid deamination of adenine arabinoside was prevented by the presence of the adenosine deaminase inhibitor EHNA, its IC50 was the same as that of ara-M. The IC50 of ara-M was not significantly changed by the presence of EHNA in this system. determined with a Varian XL-200 or XL-300 spectrometer. Coupling constants were determined by first-order analysis of the spectrum. Assignment of H2 and H8 for compound 1 was based on a HMQC analysis (36) . Other assignments for compound 1 were based on a COSY experiment. All H1, assignments were doublets (j = 5.0 to 5.2 Hz). ara-M (compound 1) was 15 times more potent than acyclovir against the Oka strain of VZV (Table 3 ). Because the shape of the inhibition curves might be relevant to the therapeutic performance of an agent in vivo, the full titration curves for ara-M and acyclovir against the Oka strain of VZV are provided in Fig. 1 . There was no appreciable difference between the shapes of these two curves.
Spectrum of antiviral activity of ara-M. The activities of ara-M against eight different strains of VZV and a variety of other pathogenic viruses of the herpes group are presented in Table 4 . The IC50s toward the eight VZV strains ranged from 0.5 to 3 ,uM. ara-M did not exhibit activity against human cytomegalovirus or against herpes simplex virus type 1 or 2. There was some inhibition of Epstein-Barr virus at 50 ,uM.
A comparison of the in vitro antiviral spectrum of ara-M with that of acyclovir is also presented in Table 4 . Against VZV, ara-M was consistently the more potent agent. As expected, neither agent exhibited appreciable activity against a thymidine kinase-deficient strain of VZV. Both agents were weak against human cytomegalovirus. Acyclovir was clearly much more potent than ara-M against herpes simplex virus types 1 and 2 and Epstein-Barr virus.
The activities of ara-M against pathogenic or model viruses not belonging to the herpes group were also explored (data not shown). No appreciable activity (IC50, >100 ,uM) was observed against influenza virus (NWS strain), respiratory syncytial virus, rhinovirus type 1B, Semliki Forest virus, Bunya virus, Mengo virus, measles virus, or human immunodeficiency virus type 1.
Enzyme studies. Thymidine kinase encoded by VZV was examined for its ability to phosphorylate the nucleoside analogs listed in Table 3 . The substrate efficiencies (relative Vmax/Ki ratios; see Materials and Methods) of the 2-unsubstituted 6-alkoxypurine arabinosides (compounds 1 through 4) correlate well with their anti-VZV activities. For example, ara-M (compound 1) was the most efficient substrate as well as the most potent anti-VZV agent. The isopropoxy congener (compound 4) was not detectably phosphorylated, nor was it appreciably active as an anti-VZV agent. The antiviral activities and substrate efficiencies of ara-H and the 6-npropoxy congener (compound 3) were similar. The 2-chloro-6-methoxy congener (compound 6) was the only example of an efficient substrate for the kinase that did not exhibit appreciable antiviral activity. The 2-amino-6-alkoxy congeners (compounds 5 and 7) had substrate efficiencies that correlated with their antiviral activities. However, ara-G had no detectable substrate activity, yet had antiviral activity comparable to that of ara-H. Relevant to this is the observation that ara-G is a relatively efficient substrate for mammalian deoxycytidine kinase (7, 21) . Thus, it is possible that differences in phosphorylation mechanism or intracellular anabolism may account for the exceptions to a regular relationship between substrate efficiency and anti-VZV potency. b Values for the Oka strain were obtained by using an enzyme-linked immunosorbent assay (35) ; values for other VZV strains were obtained by plaque reduction (4) .
CV-1 (ATCC CCL 70) is an African green monkey kidney cell line.
The extent of phosphorylation of the arabinosides of 6-methoxypurine, hypoxanthine, and adenine by nucleoside kinases other than the VZV thymidine kinase was explored (Table 5 ). In contrast to its vigorous substrate activity with the VZV thymidine kinase, ara-M at 1 mM was only poorly phosphorylated by the thymidine kinase from herpes simplex virus type 1. Furthermore, it was not detectably phosphorylated by the cellular thymidine, deoxycytidine, or adenosine kinases. In contrast, ara-A was a substrate for all of the viral and cellular nucleoside kinases listed in Table 5 , except for the cellular thymidine kinase. The differences in the ability of these two arabinosides to serve as substrates for nucleoside kinases offer an explanation for the greater selectivity and narrower antiviral range of ara-M versus ara-A. ara-H, although less cytotoxic and less active than ara-A, is slowly but detectably phosphorylated by the cellular enzyme deoxycytidine kinase. This is in agreement with earlier findings (21) .
General comments. The synthesis of ara-M was reported in 1962 by Reist et al. (26) . To our knowledge, no biological activities of this arabinoside have been reported. Revealed here is its surprisingly favorable in vitro chemotherapeutic index as an anti-VZV agent. The basis for its unexpected potency and selectivity is shown here to be its effective phosphorylation by the VZV-encoded thymidine kinase and its lack of substrate activity with the nucleoside kinases of 
